Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program

Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program

Histone modifications in cancer can contribute to pathogenesis. Here, the authors demonstrate that targeting epigenetic modifier Ezh2 hinders metastatic behaviour in Luminal B breast cancer models, and highlight a mechanism where Ezh2 contributes to metastatic behaviour by repression of FOXC1.

Guardado en:
Detalles Bibliográficos
Autores principales: Alison Hirukawa, Harvey W. Smith, Dongmei Zuo, Catherine R. Dufour, Paul Savage, Nicholas Bertos, Radia M. Johnson, Tung Bui, Guillaume Bourque, Mark Basik, Vincent Giguère, Morag Park, William J. Muller
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/08e7c695e7a0496dbcbb93d281626f1b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Histone modifications in cancer can contribute to pathogenesis. Here, the authors demonstrate that targeting epigenetic modifier Ezh2 hinders metastatic behaviour in Luminal B breast cancer models, and highlight a mechanism where Ezh2 contributes to metastatic behaviour by repression of FOXC1.

Ejemplares similares